Hope Rugo, MD
Professor
Medicine
School of Medicine

She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and a is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

Outside of work, Dr. Rugo spends time with her two children, Philip and Alyssa-Faith, and her husband Martin. Her outside interests include bicycling, hiking, travel with her family and playing the flute.

• Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
  Breast cancer research and treatment 2024 Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ
• A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.
  Future oncology (London, England) 2024 Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Murillo SM, Park YH, Sohn JH, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin E, Grinsted L, …
• Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
  Nature medicine 2024 Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, …
• Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
  Nature medicine 2024 Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, …
• Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst …
• Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC.
  NPJ breast cancer 2024 Im SA, Cortes J, Cescon DW, Yusof MM, Iwata H, Masuda N, Takano T, Huang CS, Chung CF, Tsugawa K, Park YH, Matsumoto K, Inoue K, Kwong A, Loi S, Fu W, Pan W, Karantza V, Rugo HS, Schmid P
• Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
  The oncologist 2024 Rugo HS, Schmid P, Tolaney SM, Dalenc F, Marmé F, Shi L, Verret W, Shah A, Gharaibeh M, Bardia A, Cortes J
• Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.
  ESMO open 2024 Rugo HS, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Jhaveri KL, Krivorotko P, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Sohn J, Toi M, Iwata H, Yousef S, Zhukova L, …
• Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes.
  The Journal of clinical investigation 2024 Winkler J, Tan W, Diadhiou CM, McGinnis CS, Abbasi A, Hasnain S, Durney S, Atamaniuc E, Superville D, Awni L, Lee JV, Hinrichs JH, Wagner PS, Singh N, Hein MY, Borja M, Detweiler AM, Liu SY, Nanjaraj …
• Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
  The Lancet. Oncology 2024 Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, …
• Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502.
  NPJ breast cancer 2024 Stover DG, Salgado R, Savenkov O, Ballman K, Mayer EL, Magbanua MJM, Loi S, Vater M, Glover K, Watson M, Wen Y, Symmans WF, Perou C, Carey LA, Partridge AH, Rugo HS
• Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
  Nature medicine 2024 Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M,…
• Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
  Lancet (London, England) 2024 Rugo HS, Bardia A, Tolaney S
• Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study.
  Future oncology (London, England) 2024 Johnston SRD, Rugo HS, Tolaney SM, Munoz Fernandez M, Wei R, Martin M
• Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
  Cancer 2024 Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, El Saghir NS, Penault-Llorca F, Perez EA, …
• Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ breast cancer 2024 Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM
• Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2024 Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, …
• Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
  NPJ breast cancer 2024 Cheang MCU, Rimawi M, Johnston S, Jacobs SA, Bliss J, Pogue-Geile K, Kilburn L, Zhu Z, Schuster EF, Xiao H, Swaim L, Deng S, Lu DR, Gauthier E, Tursi J, Slamon DJ, Rugo HS, Finn RS, Liu Y
• Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, …
• OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
  Future oncology (London, England) 2024 Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA
• Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.
  Breast cancer research and treatment 2024 Huppert LA, Fisch S, Tsopurashvili E, Somepalle SS, Salans M, Vasudevan HN, Jo Chien A, Majure M, Rugo HS, Balassanian R, Boreta L, Melisko ME
• Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Cortés J, Hurvitz SA, O'Shaughnessy J, Delaloge S, Iwata H, Rugo HS, Neven P, Kanagavel D, Cohen P, Paux G, Cartot-Cotton S, Stefanova-Urena M, Deyme L, Aouni J, Sebastien B, Bardia A
• Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ breast cancer 2024 Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K
• Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.
  ESMO open 2024 Marmé F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J…
• 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024 Kline B, Yadav S, Seo Y, Ippisch RC, Castillo J, Aggarwal RR, Kelley RK, Behr SC, Flavell RR, Lawhn-Heath C, Melisko M, Rugo HS, Wang V, Yom SS, Ha P, Jiang F, Hope TA
• Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer …
• Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
  Nature medicine 2024 Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, Mita M, Clay T, Chae YS, Oakman C, Yan F, Kim GM, Im SA, Lindeman GJ, Rugo HS, Liyanage M,…
• Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary.
  Future oncology (London, England) 2024 Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS
• 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).
  Breast (Edinburgh, Scotland) 2024 Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso MJ, Carey LA, Chavez-MacGregor M, Chidebe R, …
• Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.
  Journal of the National Cancer Institute 2024 Cescon DW, Schmid P, Rugo HS, Im SA, Md Yusof M, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J
• Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
  NPJ breast cancer 2024 Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, Johnston SRD, Martin M, Rastogi P, Harbeck N, Shahir A, Wei R, André V, Rugo HS, O'Shaughnessy J
• Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ breast cancer 2024 Hurvitz SA, Bardia A, Punie K, Kalinsky K, Carey LA, Rugo HS, Diéras V, Phan S, Delaney R, Zhu Y, Tolaney SM
• Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Ríos-Hoyo A, Cobain E, Huppert LA, Beitsch PD, Buchholz TA, Esserman L, van 't Veer LJ, Rugo HS, Pusztai L
• Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
  The Lancet. Oncology 2024 Layman RM, Han HS, Rugo HS, Stringer-Reasor EM, Specht JM, Dees EC, Kabos P, Suzuki S, Mutka SC, Sullivan BF, Gorbatchevsky I, Wesolowski R
• Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
  Current ophthalmology reports 2024 Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, Farooq AV, Huppert LA, Rugo HS, Pohlmann PR, Lu J, Esserman LJ, Pasricha ND
• Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study.
  Future oncology (London, England) 2024 Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Tomlin-Harris T, Brufsky A
• The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life.
  JCO oncology practice 2024 Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A
• A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
  Breast cancer research : BCR 2024 Rodón J, Demanse D, Rugo HS, Burris HA, Simó R, Farooki A, Wellons MF, André F, Hu H, Vuina D, Quadt C, Juric D
• Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan…
• Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy…
• Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.
  The Lancet. Oncology 2024 Palmieri C, Linden H, Birrell SN, Wheelwright S, Lim E, Schwartzberg LS, Dwyer AR, Hickey TE, Rugo HS, Cobb P, O'Shaughnessy JA, Johnston S, Brufsky A, Tilley WD, Overmoyer B
• International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
  The Lancet. Oncology 2024 Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, …
• A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
  Future oncology (London, England) 2024 Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Spears PA, Tolaney SM
• Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS
• Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San …
• Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.
  Breast cancer research and treatment 2024 Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ
• Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.
  JCO global oncology 2024 Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El …
• Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
  Breast cancer research and treatment 2023 Rugo HS, Van Poznak CH, Neven P, Danielewicz I, Lee SC, Campone M, Chik JYK, Vega Alonso E, Naume B, Brain E, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE
• Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO).
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2023 Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, …
• Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Huppert LA, Rugo HS
• Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer.
  Therapeutic advances in medical oncology 2023 Jhaveri K, O'Shaughnessy J, Fasching PA, Tolaney SM, Yardley DA, Sharma VK, Biswas C, Thuerigen A, Pathak P, Rugo HS
• Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
  Cell reports. Medicine 2023 Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, …
• Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective.
  Clinical advances in hematology & oncology : H&O 2023 Rugo HS
• Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2023 Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, …
• Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study.
  European journal of cancer (Oxford, England : 1990) 2023 García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnant M, Makris A, Seiler S, Burchardi N, Nekljudova …
• Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice.
  Cancers 2023 Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS
• The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
  Future oncology (London, England) 2023 Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V
• Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
  NPJ breast cancer 2023 Record H, Clelland E, Rothschild HT, Kaur M, Chien AJ, Melisko M, Rugo HS, Mujir F, Huppert L, Mukhtar RA
• Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
  International journal of cancer 2023 Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A
• A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer.
  Breast cancer research and treatment 2023 Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS
• Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
  NPJ breast cancer 2023 Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Hopkins JF, Albacker LA, Chelliserry J, Chen Y, Conte U, Wardley AM, Robson ME
• Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey.
  The oncologist 2023 Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, Fasching PA, Moore A, de Courcy J, Pathak P, Haftchenary S, Aubel D, Schumacher-Wulf E
• Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
  The oncologist 2023 Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A
• Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older.
  Frontiers in oncology 2023 Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS
• Glutaminase (GLS1) gene expression in primary breast cancer.
  Breast cancer (Tokyo, Japan) 2023 Vidula N, Yau C, Rugo HS
• Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
  Lancet (London, England) 2023 Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM
• Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, Amiri-Kordestani L, Basho RK, Best AF, Boileau JF, Denkert C, Foster JC, Harbeck N, Jacene HA, King TA, Mason G, O'Sullivan CC, …
• Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis.
  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2023 Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skyttä T, Becherini C, Coles CE, Kaidar-Person O, Offersen B, de Azambuja E, Visani L, Cortes J, Harbeck N, Rugo HS, Isacke CM, Marangoni E, Morandi …
• Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
  Clinical breast cancer 2023 Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, Chien AJ
• Bridging the "Know-Do" Gaps in Five Non-Communicable Diseases Using a Common Framework Driven by Implementation Science.
  Journal of healthcare leadership 2023 Donohue JF, Elborn JS, Lansberg P, Javed A, Tesfaye S, Rugo H, Duddi SRD, Jithoo N, Huang PH, Subramaniam K, Ramanjinappa N, Koltun A, Melamed S, Chan JCN
• Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: breast cancer.
  Clinical advances in hematology & oncology : H&O 2023 Rugo HS
• TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
  Future oncology (London, England) 2023 Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, …
• Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
  Cancer treatment reviews 2023 Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, …
• XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
  Breast cancer research : BCR 2023 Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P, Lemieux J, García-Sáenz JÁ, Hart L, Biyukov T, Baktash N, Massey D, Burris HA, Rugo HS
• Clinical course of multiple sclerosis and patient experiences during breast cancer treatment.
  Multiple sclerosis (Houndmills, Basingstoke, England) 2023 Nylander AN, Singh J, Poole S, Anderson A, Marrie RA, Rugo H, Bove R
• Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
  The New England journal of medicine 2023 Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de …
• NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
  Journal of the National Comprehensive Cancer Network : JNCCN 2023 Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, …
• Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
  JCO oncology practice 2023 Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, Westbrook KE, Buys SS
• Margetuximab in HER2-positive metastatic breast cancer.
  Future oncology (London, England) 2023 Gradishar WJ, O'Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS
• Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
  Cancer cell 2023 Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, …
• Impact of Prior Authorization on Patient Access to Cancer Care.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2023 Trapani D, Kraemer L, Rugo HS, Lin NU
• High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease.
  NPJ breast cancer 2023 Im KW, Huppert LA, Malevanchik L, Rugo HS, Combes AJ, Campbell MJ, Krummel MF, Melisko ME
• Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
  JCO precision oncology 2023 Loi S, Salgado R, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS, De Laurentiis M, Nanda R, Iwata H, Awada A, Tan AR, Sun Y, Karantza V, Wang A, Huang L, Saadatpour A, Cristescu R, …
• Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer.
  Breast (Edinburgh, Scotland) 2023 Rugo HS, Liu X, Li B, McRoy L, Layman RM, Brufsky A
• Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.
  CA: a cancer journal for clinicians 2023 Huppert LA, Gumusay O, Idossa D, Rugo HS
• Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, Sivakumar S, Lee JK, Fisher V, Oxnard GR, Tukachinsky H
• Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
  The Lancet. Oncology 2023 Tolaney SM, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, …
• Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison.
  Therapeutic advances in medical oncology 2023 Rugo HS, Harmer V, O'Shaughnessy J, Jhaveri K, Tolaney SM, Cardoso F, Bardia A, Maheshwari VK, Tripathi S, Haftchenary S, Pathak P, Fasching PA
• Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701).
  Seminars in oncology 2023 Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo HS, Loprinzi C
• Reply to G.-F. Li et al, K. Altundag, and N. SG et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Rugo HS, Bardia A, Tolaney SM
• Role of Immunotherapy in Breast Cancer.
  JCO oncology practice 2023 Jacob SL, Huppert LA, Rugo HS
• Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
  British journal of cancer 2023 Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, …
• Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
  Breast (Edinburgh, Scotland) 2022 Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N…
• Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
  The Lancet. Oncology 2022 Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A…
• Management of breast cancer diagnosed during pregnancy: global perspectives.
  Expert review of anticancer therapy 2022 Bajpai J, Pathak R, Shylasree TS, Rugo HS
• Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
  NPJ breast cancer 2022 Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS,…
• Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
  Nature communications 2022 Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, …
• Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
  Breast (Edinburgh, Scotland) 2022 Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V
• Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study.
  Journal of immigrant and minority health 2022 Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ
• A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
  British journal of cancer 2022 Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, …
• Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
  NPJ breast cancer 2022 Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, Paz-Ares L, Chisamore MJ, Chapman SC, Hossain AM, Chen Y, Tolaney SM
• Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR, Levy C, Brown-…
• Reply to Z.R. McCaw et al.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Rugo HS, Umanzor GA, Kwan MR, Cutler DL
• Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study.
  Breast cancer research and treatment 2022 Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, Melisko ME, Rugo HS, Behr S, Chien AJ
• ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
  Annals of surgical oncology 2022 Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA
• GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.
  Future oncology (London, England) 2022 Rugo HS, Cortes J, Barrios CH, Cabrera P, Xu B, Huang CS, Kim SB, Melisko M, Nanda R, Pienkowski T, Rapoport BL, Schwab R
• Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
  Breast (Edinburgh, Scotland) 2022 Shastry M, Jacob S, Rugo HS, Hamilton E
• Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
  European journal of cancer (Oxford, England : 1990) 2022 Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, O'Shaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, …
• Little Downside.
  International journal of radiation oncology, biology, physics 2022 Singer L, Rugo HS
• First, do no harm: risk of secondary cancer after breast cancer treatment.
  The Lancet. Oncology 2022 Rugo HS, Singer L
• Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
  NPJ breast cancer 2022 Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A
• Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).
  Breast cancer research and treatment 2022 Loeser AL, Gao L, Bardia A, Burkard ME, Kalinsky KM, Peppercorn J, Rugo HS, Carlson M, Cowden J, Glenn L, Maues J, McGlown S, Ni A, Padron N, Lustberg M
• Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
  Future oncology (London, England) 2022 Goel S, Tan AR, Rugo HS, Aftimos P, Andric Z, Beelen A, Zhang J, Yi JS, Malik R, O'Shaughnessy J
• PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
  BMC cancer 2022 Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, Park J, Dua A, Rugo HS
• Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.
  Frontiers in oncology 2022 Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Gnant M, Makris A, Burchardi N,…
• Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
  NPJ breast cancer 2022 Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K
• Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM
• Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.
  NPJ precision oncology 2022 Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y
• Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ,…
• Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
  ESMO open 2022 Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M
• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
  The New England journal of medicine 2022 Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P, …
• Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Rugo HS, Umanzor GA, Barrios FJ, Vasallo RH, Chivalan MA, Bejarano S, Ramírez JR, Fein L, Kowalyszyn RD, Kramer ED, Wang H, Kwan MR, Cutler DL, Oraxol Study Consortium Investigators
• The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
  Annals of surgical oncology 2022 Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA
• The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage.
  Cancer discovery 2022 Morgan G, Agarwal N, Choueiri TK, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HL
• Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
  Breast cancer research and treatment 2022 Vidula N, Yau C, Rugo H
• Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
  JAMA oncology 2022 Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J, ATTAIN Investigators
• Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
  Nature communications 2022 Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, …
• Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
  European journal of cancer (Oxford, England : 1990) 2022 Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, Cortés J, Harbeck N, Carey LA, Criscitiello C, Curigliano G
• Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
  NPJ breast cancer 2022 Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, …
• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
  The New England journal of medicine 2022 Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, …
• Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice.
  JCO precision oncology 2022 Bui TBV, Burgering BMT, Goga A, Rugo HS, van 't Veer LJ
• Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2022 Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, …
• The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer.
  Journal for immunotherapy of cancer 2022 Hung JT, Chen IJ, Ueng SH, Huang CS, Chen SC, Chen MY, Lin YC, Lin CY, Campbell MJ, Rugo HS, Yu AL
• Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis.
  Frontiers in pharmacology 2022 Liao H, Pei W, Zhong J, Shao B, Liu X, Liu Y, Zhang J, Rugo HS, Li H
• Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
  Cancer cell 2022 Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, …
• Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
  Breast cancer research and treatment 2022 O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J
• COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry.
  The oncologist 2022 Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ
• Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
  Annals of oncology : official journal of the European Society for Medical Oncology 2022 Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, …
• NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
  Journal of the National Comprehensive Cancer Network : JNCCN 2022 Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar…
• Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer.
  Journal of oncology 2022 Apple AC, Lindbergh CA, Landau SM, DeLuca A, Eberling JL, Jagust WJ, Kramer JH, Rugo HS, Heflin LH
• Emerging treatment strategies for metastatic triple-negative breast cancer.
  Therapeutic advances in medical oncology 2022 Huppert LA, Gumusay O, Rugo HS
• The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases.
  Breast (Edinburgh, Scotland) 2022 Gumusay O, Huppert LA, Behr SC, Rugo HS
• Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA
• Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
  Annals of oncology : official journal of the European Society for Medical Oncology 2022 Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, …
• Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy.
  Frontiers in oncology 2022 Magbanua MJM, Gumusay O, Kurzrock R, van 't Veer LJ, Rugo HS
• Risk-Based Screening for Cancer in Patients With Dermatomyositis: Toward a More Individualized Approach.
  JAMA dermatology 2022 Vaughan H, Rugo HS, Haemel A
• Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study.
  JMIR cancer 2022 Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M
• Immunotherapy for early triple negative breast cancer: research agenda for the next decade.
  NPJ breast cancer 2022 Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G
• Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
  NPJ breast cancer 2022 Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, …
• Reconceptualizing Risk-Benefit Assessment of Novel Cancer Therapies to Expand Global Access and Reduce Worldwide Mortality.
  JAMA oncology 2022 DeBoer RJ, Rugo HS, Shulman LN
• Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2022 Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre…
• Immunotherapy toxicity: identification and management.
  Breast cancer research and treatment 2022 Gumusay O, Callan J, Rugo HS
• Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
  British journal of cancer 2022 Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K…
• Role of Fcγ receptors in HER2-targeted breast cancer therapy.
  Journal for immunotherapy of cancer 2022 Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD
• Harmonizing PD-L1 testing in metastatic triple negative breast cancer.
  Expert opinion on biological therapy 2021 Giugliano F, Antonarelli G, Tarantino P, Cortes J, Rugo HS, Curigliano G
• A multidisciplinary approach to optimizing care of patients treated with alpelisib.
  Breast (Edinburgh, Scotland) 2021 Rugo HS, Lacouture ME, Goncalves MD, Masharani U, Aapro MS, O'Shaughnessy JA
• Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SM
• Does the cancer geriatric assessment (GA) introduce bias into clinical trials? Observations from 988 prospectively recruited patients.
  Journal of geriatric oncology 2021 Peil E, Williams GR, Rugo H, Woyach JA, Jatoi A, Le-Rademacher JG
• Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O…
• PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
  Journal of the National Cancer Institute 2021 Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Nguyen-Duc A, Viale G, Molinero L, Emens LA
• Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
  NPJ breast cancer 2021 Metzger-Filho O, Collier K, Asad S, Ansell PJ, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark…
• Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
  Nature communications 2021 Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis …
• Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P
• Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
  JAMA oncology 2021 Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, …
• Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
  NPJ breast cancer 2021 Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA
• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, …
• Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg …
• Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
  British journal of cancer 2021 Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K…
• Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
  NPJ breast cancer 2021 Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, …
• Expert Discussion: Predictive Markers.
  Breast care (Basel, Switzerland) 2021 Paradiso A, Codacci-Pisanelli G, Munzone E, Rugo HS, Heudel PE
• The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, de Abreu Alves F, Ashbury FD, Eng L, Fitch M, Jain H, Jefford M, Klemanski D, Koczwara B, Loh K, Prasad M, Rugo H, Soto-Perez-de-…
• Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid.
  NPJ breast cancer 2021 Vidula N, Greenberg S, Petrillo L, Hwang J, Melisko M, Goga A, Moasser M, Magbanua M, Park JW, Rugo HS
• A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer.
  Future oncology (London, England) 2021 Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA
• The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
  Expert review of anticancer therapy 2021 Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI
• Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
  Breast cancer research : BCR 2021 Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW
• Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
  Journal of the National Cancer Institute 2021 Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P
• Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
  Journal for immunotherapy of cancer 2021 Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK
• Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS
• Sacituzumab Govitecan in Metastatic Breast Cancer. Reply.
  The New England journal of medicine 2021 Bardia A, Hurvitz SA, Rugo HS
• Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
  The oncologist 2021 Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, Rugo H, Moy B, Bardia A
• Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
  Lancet (London, England) 2021 Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P
• First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P
• RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW
• Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
  Cancer cell 2021 Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, …
• Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
  Breast cancer research and treatment 2021 Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, Loganathan S, Deodhar S, Marwah A, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng …
• Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
  Breast cancer research and treatment 2021 Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart …
• Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
  The oncologist 2021 Rugo HS, Cristofanilli M, Loibl S, Harbeck N, DeMichele A, Iwata H, Park YH, Brufsky A, Theall KP, Huang X, McRoy L, Bananis E, Turner NC
• A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Potter DA, Thomas A, Rugo HS
• Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2021 Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat…
• Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine …
• Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
  The oncologist 2021 Turner S, Chia S, Kanakamedala H, Hsu WC, Park J, Chandiwana D, Ridolfi A, Yu CL, Zarate JP, Rugo HS
• Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
  Cancers 2021 Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, …
• NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
  Journal of the National Comprehensive Cancer Network : JNCCN 2021 Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, …
• Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
  Breast cancer research and treatment 2021 Vidula N, Yau C, Rugo HS
• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
  The New England journal of medicine 2021 Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, …
• In Reply.
  The oncologist 2021 Rugo HS, Huober J, Garcia-Saenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M
• Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).
  JNCI cancer spectrum 2021 Ligibel JA, Huebner L, Rugo HS, Burstein HJ, Toppmeyer DL, Anders CK, Ma C, Barry WT, Suman V, Carey LA, Partridge AH, Hudis CA, Winer EP
• Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Rugo HS, Huppert L
• Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
  Journal of the National Cancer Institute 2021 Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, Gazzaniga P, Manso …
• Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
  The Lancet. Oncology 2021 Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S
• Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
  JAMA oncology 2021 Filho OM, Stover DG, Asad S, Ansell PJ, Watson M, Loibl S, Geyer CE, Bae J, Collier K, Cherian M, O'Shaughnessy J, Untch M, Rugo HS, Huober JB, Golshan M, Sikov WM, von Minckwitz G, Rastogi P, Maag D,…
• Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
  Breast (Edinburgh, Scotland) 2021 Rugo HS, Pennella EJ, Gopalakrishnan U, Hernandez-Bronchud M, Herson J, Koch HF, Loganathan S, Deodhar S, Marwah A, Manikhas A, Bondarenko I, Parra JD, Abesamis-Tiambeng MLT, Akewanlop C, Vynnychenko …
• Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
  JAMA oncology 2021 Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková …
• Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Koehler M, Huang-…
• Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, André F
• Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
  Breast cancer research : BCR 2021 DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS
• Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S
• An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
  Targeted oncology 2021 Cortesi L, Rugo HS, Jackisch C
• Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
  The oncologist 2021 Finn RS, Rugo HS, Gelmon KA, Cristofanilli M, Colleoni M, Loi S, Schnell P, Lu DR, Theall KP, Mori A, Gauthier E, Bananis E, Turner NC, Diéras V
• Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
  The oncologist 2021 Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M
• Navigating a Path to Equity in Cancer Care: The Role of Patient Navigation.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2021 Dixit N, Rugo H, Burke NJ
• Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
  Breast cancer research and treatment 2021 Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M
• Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer.
  Journal of comparative effectiveness research 2021 Rugo HS, Haltner A, Zhan L, Tran A, Bananis E, Hooper B, Mitra D, Cameron C
• The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
  Breast cancer research and treatment 2021 Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A,…
• Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
  Clinical breast cancer 2021 Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS
• Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology.
  JCO global oncology 2021 Onesti CE, Tagliamento M, Curigliano G, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, …
• Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
  The Lancet. Oncology 2021 Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, …
• Highlights in metastatic breast cancer from the 2020 San Antonio Breast Cancer Symposium: commentary.
  Clinical advances in hematology & oncology : H&O 2021 Rugo HS
• Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
  The Lancet. Oncology 2021 Dent R, Rugo HS
• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
  Lancet (London, England) 2020 Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P, …
• A 4-Month Whole-Systems Ayurvedic Medicine Nutrition and Lifestyle Intervention Is Feasible and Acceptable for Breast Cancer Survivors: Results of a Single-Arm Pilot Clinical Trial.
  Global advances in health and medicine 2020 Dhruva A, Wu C, Miaskowski C, Hartogensis W, Rugo HS, Adler SR, Kaptchuk TJ, Kelkar R, Agarawal S, Vadodaria A, Garris E, Hecht FM
• Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo …
• Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
  The oncologist 2020 Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M
• Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
  Clinical breast cancer 2020 Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K,…
• Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?
  CA: a cancer journal for clinicians 2020 Cinar P, Bold R, Bosslet BA, Bota DA, Burgess D, Chew HK, Cohen JG, Elquza E, Gold KA, Kamiya E, Karlan BY, McKay RR, Patel SP, Ternavan K, Welborn J, Yamamoto M, Rugo HS
• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, …
• Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
  JAMA oncology 2020 I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-…
• Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, …
• Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, …
• Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
  Breast cancer research and treatment 2020 Rugo HS, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DA, Carter GC, Sheffield KM, Li L, Andre VAM, Li XI, Frenzel M, Huang YJ, Dickler MN, Tolaney SM
• Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
  Breast cancer research and treatment 2020 Finn RS, Cristofanilli M, Ettl J, Gelmon KA, Colleoni M, Giorgetti C, Gauthier E, Liu Y, Lu DR, Zhang Z, Bartlett CH, Slamon DJ, Turner NC, Rugo HS
• Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
  Clinical pharmacology and therapeutics 2020 Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS, Friedman PN, Ratain MJ, McLeod HL, Rugo HS, Shulman LN, Kubo M, Owzar K, Kroetz DL
• Oncological care organisation during COVID-19 outbreak.
  ESMO open 2020 Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S…
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
  Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN
• Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.
  Journal for immunotherapy of cancer 2020 Huang CS, Yu AL, Tseng LM, Chow LWC, Hou MF, Hurvitz SA, Schwab RB, L Murray J, Chang HK, Chang HT, Chen SC, Kim SB, Hung JT, Ueng SH, Lee SH, Chen CC, Rugo HS
• Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Magbanua MJM, Savenkov O, Asmus EJ, Ballman KV, Scott JH, Park JW, Dickler M, Partridge A, Carey LA, Winer EP, Rugo HS
• Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Hafez N, Rugo HS, Tempero MA, Fox E, Reaman GH, Lyerly HK, Walker D, LoRusso PM
• Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
  Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2020 Li H, Liu R, Shao B, Ran R, Song G, Wang K, Shi Y, Liu J, Hu W, Chen F, Liu X, Zhang G, Zhao C, Jia R, Wang Q, Rugo HS, Zhang Y, Li G, Xu J
• Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib.
  JCO precision oncology 2020 Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM
• Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz…
• The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
  Advances in therapy 2020 Rugo HS, Jacobs I, Sharma S, Scappaticci F, Paul TA, Jensen-Pergakes K, Malouf GG
• Management of Cancer Cachexia: ASCO Guideline.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, Rugo HS, Schnipper HH, Smith TJ, Tan W, Loprinzi CL
• Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab.
  OncoTargets and therapy 2020 Ran R, Huang W, Liu Y, Shao L, Liu X, Niu Y, Kong W, Bo S, Rugo HS, Lu S, Li H
• Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S
• Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
  Breast cancer research and treatment 2020 O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn …
• Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
  International journal of cancer 2020 Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T
• Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
  JAMA oncology 2020 Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, …
• Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2020 Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS
• Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
  Breast cancer research and treatment 2020 Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro …
• TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
  Future oncology (London, England) 2020 Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P
• Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
  Breast cancer research : BCR 2020 Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS
• MYC Dysregulates Mitosis, Revealing Cancer Vulnerabilities.
  Cell reports 2020 Rohrberg J, Van de Mark D, Amouzgar M, Lee JV, Taileb M, Corella A, Kilinc S, Williams J, Jokisch ML, Camarda R, Balakrishnan S, Shankar R, Zhou A, Chang AN, Chen B, Rugo HS, Dumont S, Goga A
• Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
  JAMA surgery 2020 Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M
• Highlights from the 2019 San Antonio Breast Cancer Symposium.
  Clinical advances in hematology & oncology : H&O 2020 Rugo HS
• Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
  Annals of oncology : official journal of the European Society for Medical Oncology 2020 Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, Rugo HS, Emens LA, Schmid P
• TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
  Breast cancer research : BCR 2020 Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A, …
• Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Stebbing J, Mainwaring PN, Curigliano G, Pegram M, Latymer M, Bair AH, Rugo HS
• Using diagnosis codes in claims data to identify cohorts of breast cancer patients following initial treatment.
  The breast journal 2020 Franc BL, Thombley R, Luo Y, John Boscardin W, Rugo HS, Seidenwurm D, Dudley RA
• Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
  Clinical breast cancer 2020 Kittaneh M, Badve S, Caldera H, Coleman R, Goetz MP, Mahtani R, Mamounas E, Kalinsky K, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Traina T, Vogel C
• Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer.
  Technology in cancer research & treatment 2020 Liu XR, Zhang RY, Gong H, Rugo HS, Chen LB, Fu Y, Che JW, Tie J, Shao B, Wan FL, Kong WY, Song GH, Jiang HF, Xu GB, Li HP
• NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
  Journal of the National Comprehensive Cancer Network : JNCCN 2020 Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S,…
• Androgen receptor gene expression in primary breast cancer.
  NPJ breast cancer 2019 Vidula N, Yau C, Wolf D, Rugo HS
• Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
  Journal of clinical pharmacology 2019 Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV
• Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
  The Lancet. Oncology 2019 Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Investigators
• Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M
• Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
  The oncologist 2019 Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J
• Identifying tests related to breast cancer care in claims data.
  The breast journal 2019 Franc BL, Thombley R, Luo Y, Boscardin WJ, Rugo HS, Seidenwurm D, Dudley RA
• Treatment of early-stage hormone receptor-positive breast cancer.
  Clinical advances in hematology & oncology : H&O 2019 Rugo HS
• Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
  JNCI cancer spectrum 2019 Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, …
• De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
  The oncologist 2019 Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA
• Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial.
  European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2019 Golshan M, Wong SM, Loibl S, Huober JB, O'Shaughnessy J, Rugo HS, Wolmark N, Ansell P, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE, Sikov WM, Untch M
• Cyclin-dependent kinase 4/6 inhibition in the treatment of hormone receptor-positive breast cancer.
  Clinical advances in hematology & oncology : H&O 2019 Rugo HS
• Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Finn RS, Liu Y, Zhu Z, Martin M, Rugo HS, Diéras V, Im SA, Gelmon KA, Harbeck N, Lu DR, Gauthier E, Huang Bartlett C, Slamon DJ
• Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
  Clinical breast cancer 2019 Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, Mukai H, Walshe JM, Mori A, Gauthier E, Lu DR, Bananis E, Martin M, Diéras V
• A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
  Annals of oncology : official journal of the European Society for Medical Oncology 2019 Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ
• Phosphoinositide 3-kinase inhibition in the treatment of hormone receptor-positive breast cancer.
  Clinical advances in hematology & oncology : H&O 2019 Rugo HS
• Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
  The breast journal 2019 Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ
• A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
  Clinical breast cancer 2019 Mahtani R, Holmes FA, Badve S, Caldera H, Coleman R, Mamounas E, Kalinsky K, Kittaneh M, Lower E, Pegram M, Press MF, Rugo HS, Schwartzberg L, Vogel C, Breast Cancer Therapy Expert Group (BCTEG)
• Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes.
  JNCI cancer spectrum 2019 Uno H, Schrag D, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ
• Achieving Improved Survival Outcomes in Advanced Breast Cancer.
  The New England journal of medicine 2019 Rugo HS
• Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
  Therapeutic advances in medical oncology 2019 Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS
• Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
  The oncologist 2019 Diéras V, Harbeck N, Joy AA, Gelmon K, Ettl J, Verma S, Lu DR, Gauthier E, Schnell P, Mori A, Rugo HS, Finn RS
• A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
  NPJ breast cancer 2019 Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ
• Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.
  Breast cancer research and treatment 2019 Melisko ME, Assefa M, Hwang J, DeLuca A, Park JW, Rugo HS
• Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
  Clinical breast cancer 2019 Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME
• Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
  The New England journal of medicine 2019 André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D…
• ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases.
  Future oncology (London, England) 2019 Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Dieras V, Müller V, Tagliaferri M, Hannah AL, Cortés J
• Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
  Breast cancer research and treatment 2019 Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM
• Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
  Cancer medicine 2019 Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V
• Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
  Plastic and reconstructive surgery. Global open 2019 Mukhtar RA, Holland M, Sieber DA, Wen KW, Rugo HS, Kadin ME, Bean GR
• Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, …
• Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
  Journal of the National Cancer Institute 2019 Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS
• Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
  Annals of oncology : official journal of the European Society for Medical Oncology 2019 Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, …
• Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
  Annals of oncology : official journal of the European Society for Medical Oncology 2019 Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P
• Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
  The New England journal of medicine 2019 Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM…
• MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, …
• Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
  JAMA oncology 2019 Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS
• NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
  Journal of the National Comprehensive Cancer Network : JNCCN 2019 Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, …
• The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.
  Breast cancer research and treatment 2019 Rugo HS, Di Palma JA, Tripathy D, Bryce R, Moran S, Olek E, Bosserman L
• Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
  Breast cancer research and treatment 2019 Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ
• Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M
• A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME, ABRAZO Study Group
• T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe …
• Demystifying biosimilars: development, regulation and clinical use.
  Future oncology (London, England) 2018 Rugo HS, Rifkin RM, Declerck P, Bair AH, Morgan G
• A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).
  Clinical pharmacology and therapeutics 2018 Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL
• Geographic and Patient Characteristics Associated With Election of Prophylactic Mastectomy in Young Breast Cancer Patients With Early Disease.
  American journal of clinical oncology 2018 Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean M, Boscardin WJ, Rugo HS, Dudley RA
• Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
  European journal of cancer (Oxford, England : 1990) 2018 Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM
• Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
  The New England journal of medicine 2018 Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 …
• Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.
  NPJ breast cancer 2018 Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW
• Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer.
  American journal of cancer research 2018 Li H, Xu Y, Zhao F, Song G, Rugo HS, Zhang Y, Yang L, Liu X, Shao B, Yang L, Liu Y, Ran R, Zhang R, Guan Y, Chang L, Yi X
• Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2018 Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK
• Advance Care Planning in Community: An Evaluation of a Pilot 2-Session, Nurse-Led Workshop.
  The American journal of hospice & palliative care 2018 Rabow MW, McGowan M, Small R, Keyssar R, Rugo HS
• Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
  The New England journal of medicine 2018 Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL
• Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.
  Clinical breast cancer 2018 Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L
• 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
  Annals of oncology : official journal of the European Society for Medical Oncology 2018 Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El…
• Circulating Tumors Cells as a Biomarker of Radiation Benefit.
  JAMA oncology 2018 Speers C, Rugo HS
• Highlights in breast cancer from the 2018 American Society of Clinical Oncology annual meeting.
  Clinical advances in hematology & oncology : H&O 2018 Rugo HS
• Reply to the letter to the editor 'Reporting of HRQoL results from the PALOMA-2 trial: unfounded conclusions due to highly biased analyses' by Kaiser et al.
  Annals of oncology : official journal of the European Society for Medical Oncology 2018 Rugo HS, Iyer S, Huang C
• Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
  European journal of cancer (Oxford, England : 1990) 2018 Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N, Masuda N, Im SA, Huang X, Kim S, Sun W, Iyer S, Schnell P, Bartlett CH, Johnston S
• The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.
  Future oncology (London, England) 2018 Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS
• Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
  Journal of the National Comprehensive Cancer Network : JNCCN 2018 Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA
• Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain …
• Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer.
  Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2018 Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H
• A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
  Breast cancer research and treatment 2018 O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS
• The new world of biosimilars in oncology: Translation of data to the clinic.
  European journal of cancer (Oxford, England : 1990) 2018 Rugo HS, Cortes J
• Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Rugo HS, Cortes J, Awada A, O'Shaughnessy J, Twelves C, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri M, Hoch U, Perez EA
• Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
  Annals of oncology : official journal of the European Society for Medical Oncology 2018 Rugo HS, Diéras V, Gelmon KA, Finn RS, Slamon DJ, Martin M, Neven P, Shparyk Y, Mori A, Lu DR, Bhattacharyya H, Bartlett CHUANG, Iyer S, Johnston S, Ettl J, Harbeck N
• Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR
• Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
  Anti-cancer drugs 2018 Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, Finn RS, Joy AA, Ettl J, Rugo HS, Zheng J, Wilner KD, Wang DD
• Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
  The Lancet. Oncology 2018 Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans …
• Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.
  Journal of the American Dental Association (1939) 2018 Chambers MS, Rugo HS, Litton JK, Meiller TF
• Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin…
• Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
  Breast cancer research and treatment 2018 Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C
• Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW
• TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.
  Cancer cell 2018 de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B
• Emerging data on improving response to hormone therapy: the role of novel targeted agents.
  Expert review of anticancer therapy 2017 Vidula N, Rugo HS
• 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L…
• Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2017 Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, …
• Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A
• Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
  Breast cancer research and treatment 2017 Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL,…
• Real-world use of scalp cooling to reduce chemotherapy-related hair loss.
  Clinical advances in hematology & oncology : H&O 2017 Rugo HS
• Dual HER2 Blockade.
  Breast care (Basel, Switzerland) 2017 Thomssen C, El Saghir NS, Francis PA, Jassem J, Rugo HS, Untch M
• The value of embedding: integrated palliative care for patients with metastatic breast cancer.
  Breast cancer research and treatment 2017 Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H
• Use of Neoadjuvant Platinum-The Ongoing Conundrum.
  JAMA oncology 2017 Rugo HS, Gelmon K
• Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
  Breast cancer research and treatment 2017 Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME
• DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
  NPJ breast cancer 2017 Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, …
• Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer.
  Cancer research 2017 Gulbahce N, Magbanua MJM, Chin R, Agarwal MR, Luo X, Liu J, Hayden DM, Mao Q, Ciotlos S, Li Z, Chen Y, Chen X, Li Y, Zhang RY, Lee K, Tearle R, Park E, Drmanac S, Rugo HS, Park JW, Drmanac R, Peters …
• Scalp Hypothermia for Preventing Alopecia During Chemotherapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
  Clinical breast cancer 2017 Rugo HS, Voigt J
• Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Chien AJ, Rugo HS
• Concerns About Methodology of a Trial Investigating Vaginal Health During Aromatase Inhibitor Therapy for Breast Cancer-Reply.
  JAMA oncology 2017 Melisko ME, Hwang J, Rugo HS
• Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
  Breast cancer research and treatment 2017 Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP
• Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.
  JAMA oncology 2017 Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, …
• Highlights in breast cancer from the 2017 American Society of Clinical Oncology Annual Meeting.
  Clinical advances in hematology & oncology : H&O 2017 Rugo HS
• A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
  Breast cancer research and treatment 2017 Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, Baselga J
• NCCN Guidelines Insights: Antiemesis, Version 2.2017.
  Journal of the National Comprehensive Cancer Network : JNCCN 2017 Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, …
• Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
  The AAPS journal 2017 Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV
• Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
  Breast cancer research and treatment 2017 Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL,…
• Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
  Breast cancer research and treatment 2017 Vidula N, Yau C, Li J, Esserman LJ, Rugo HS
• MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J
• Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
  Breast cancer research and treatment 2017 Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP
• Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC
• Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
  European journal of cancer (Oxford, England : 1990) 2017 Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, …
• A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
  Breast cancer research and treatment 2017 Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS
• Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
  The Lancet. Oncology 2017 Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK
• Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
  CA: a cancer journal for clinicians 2017 Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN
• Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
  Breast (Edinburgh, Scotland) 2017 Rugo HS, Rossi G, Rizzi G, Aapro M
• Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis.
  Breast cancer research and treatment 2017 Rugo HS, Melin SA, Voigt J
• Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
  JAMA oncology 2017 Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS
• Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
  JAMA 2017 Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T
• Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].
  Breast (Edinburgh, Scotland) 2017 Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L…
• Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
  JAMA 2017 Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-…
• 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
  Annals of oncology : official journal of the European Society for Medical Oncology 2017 Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L…
• Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer.
  Advances in experimental medicine and biology 2017 Rugo HS, Li H, Gui X
• 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).
  Breast (Edinburgh, Scotland) 2016 Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L…
• Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.
  Current opinion in supportive and palliative care 2016 Dawood S, Rugo HS
• NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016 Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H
• Palbociclib and Letrozole in Advanced Breast Cancer.
  The New England journal of medicine 2016 Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ
• NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.
  Journal of the National Comprehensive Cancer Network : JNCCN 2016 VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, …
• When to Treat, With What, and for How Long: That Is the Question!
  Journal of oncology practice 2016 Dawood S, Rugo HS
• PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
  Nature medicine 2016 Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo …
• Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
  SpringerPlus 2016 Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, O'Shaughnessy J
• Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
  The New England journal of medicine 2016 Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS,…
• Highlights in breast cancer from the 2016 American Society of Clinical Oncology Annual Meeting.
  Clinical advances in hematology & oncology : H&O 2016 Rugo HS
• Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
  The oncologist 2016 Verma S, Bartlett CH, Schnell P, DeMichele AM, Loi S, Ro J, Colleoni M, Iwata H, Harbeck N, Cristofanilli M, Zhang K, Thiele A, Turner NC, Rugo HS
• Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
  Cancer medicine 2016 Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF
• Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.
  Oncotarget 2016 Morrison G, Lenkala D, LaCroix B, Ziliak D, Abramson V, Morrow PK, Forero A, Van Poznak C, Rugo HS, Nanda R, O'Donnell PH, Huang RS
• Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ
• Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Wolff AC, Rugo HS
• Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA
• A clinician's guide to biosimilars in oncology.
  Cancer treatment reviews 2016 Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I
• A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
  Breast cancer research and treatment 2016 Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN
• Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers.
  Breast cancer research and treatment 2016 Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU
• HER2-positive breast cancer: is more treatment better?
  The Lancet. Oncology 2016 Rugo HS, Chien AJ
• Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
  Annals of oncology : official journal of the European Society for Medical Oncology 2016 Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, Ringeisen F, Gallo J, Rouyrre N, Anak O, Motzer R
• Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
  JAMA oncology 2016 Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM
• Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2016 Rugo HS, Vidula N, Ma C
• Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options.
  Therapeutic advances in medical oncology 2015 Jiang H, Rugo HS
• Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer.
  Breast cancer research and treatment 2015 Lee JS, Melisko ME, Magbanua MJ, Kablanian AT, Scott JH, Rugo HS, Park JW
• Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER, …
• A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.
  PloS one 2015 Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A, Rugo HS, Park JW
• Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
  The Lancet. Oncology 2015 Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, …
• Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
  Clinical breast cancer 2015 Rugo HS
• A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
  BioMed research international 2015 Hesketh PJ, Aapro M, Jordan K, Schwartzberg L, Bosnjak S, Rugo H
• Cancer-Related Fatigue, Version 2.2015.
  Journal of the National Comprehensive Cancer Network : JNCCN 2015 Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, …
• Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
  Clinical breast cancer 2015 Vidula N, Rugo HS
• Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
  Breast cancer research and treatment 2015 Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP
• In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
  Mayo Clinic proceedings 2015 Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD…
• The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting.
  Cancer management and research 2015 Palli SR, Grabner M, Quimbo RA, Rugo HS
• Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP
• Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
  Breast cancer research : BCR 2015 Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ
• Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
  Breast cancer research and treatment 2015 Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, …
• TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW
• Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.
  Breast cancer research and treatment 2015 Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ
• TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ, Krontiras H, De Los Santos JF, …
• Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.
  Cancer 2015 Vaz-Luis I, Hughes ME, Cronin AM, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU
• New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomiting.
  Clinical advances in hematology & oncology : H&O 2015 Schwartzberg LS, Rugo HS, Aapro MS
• The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, …
• Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
  The New England journal of medicine 2015 Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP
• Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
  Breast cancer research and treatment 2015 Liu S, Chapman JA, Burnell MJ, Levine MN, Pritchard KI, Whelan TJ, Rugo HS, Albain KS, Perez EA, Virk S, Barry G, Gao D, O'Brien P, Shepherd LE, Nielsen TO, Gelmon KA
• Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE
• Circulating tumor cell analysis in metastatic triple-negative breast cancers.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS, Translational Breast Cancer Research Consortium
• SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer.
  Cancer 2014 Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME
• Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
  Clinical therapeutics 2014 Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H
• Translating the molecular message of triple-negative breast cancer into targeted therapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Vidula N, Rugo HS
• Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, …
• Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.
  Cancer cell 2014 Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM
• A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
  Breast cancer research and treatment 2014 Miller KD, Althouse SK, Nabell L, Rugo H, Carey L, Kimmick G, Jones DR, Merino MJ, Steeg PS
• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
  Breast (Edinburgh, Scotland) 2014 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, …
• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
  Annals of oncology : official journal of the European Society for Medical Oncology 2014 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, …
• Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
  Annals of oncology : official journal of the European Society for Medical Oncology 2014 Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, …
• Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network.
  Clinical breast cancer 2014 Mayadev J, Einck J, Elson S, Rugo H, Hwang S, Bold R, Daroui P, McCloskey S, Yashar C, Kim D, Fowble B
• Evidence-driven, patient-specific approaches for optimizing survival prolongation in breast cancer.
  Clinical advances in hematology & oncology : H&O 2014 Gradishar WJ, Twelves C, Rugo HS
• Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond.
  Annals of oncology : official journal of the European Society for Medical Oncology 2014 Rugo HS, Aapro M
• Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.
  International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2014 Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL,…
• Hormone therapy in premenopausal women with early-stage breast cancer.
  The New England journal of medicine 2014 Rugo HS
• The cancer glycocalyx mechanically primes integrin-mediated growth and survival.
  Nature 2014 Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, …
• Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
  Cancer 2014 Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL
• Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU
• The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
  BMC cancer 2014 Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S
• Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.
  British journal of cancer 2014 Yardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M
• Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM
• Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
  Breast cancer research and treatment 2014 Yardley DA, Kaufman PA, Brufsky A, Yood MU, Rugo H, Mayer M, Quah C, Yoo B, Tripathy D
• Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
  Annals of oncology : official journal of the European Society for Medical Oncology 2014 Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T…
• A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.
  Annals of oncology : official journal of the European Society for Medical Oncology 2014 Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S
• Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.
  Clinical advances in hematology & oncology : H&O 2014 Morrow GR, Navari RM, Rugo HS
• Informational needs of patients with metastatic breast cancer: what questions do they ask, and are physicians answering them?
  Journal of cancer education : the official journal of the American Association for Cancer Education 2014 Danesh M, Belkora J, Volz S, Rugo HS
• Management of chemotherapy-induced nausea and vomiting in clinical practice.
  Clinical advances in hematology & oncology : H&O 2014 Rugo HS
• ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer.
  Indian journal of cancer 2014 Parikh PM, Gupta S, Dawood S, Rugo H, Bhattacharyya GS, Agarwal A, Chacko R, Sahoo TP, Babu G, Agarwal S, Munshi A, Goswami C, Smruti BK, Bondarde S, Desai C, Rajappa S, Somani N, Singh M, Nimmagadda …
• Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .
  Journal of the National Comprehensive Cancer Network : JNCCN 2014 Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, Dotan E, Edil BH, Extermann M, Ganti AK, Holmes HM, Jagsi R, Karlekar MB, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, …
• Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
  Breast cancer research and treatment 2013 Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, …
• Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
  Clinical breast cancer 2013 Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K…
• Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
  Advances in therapy 2013 Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, …
• Myeloid growth factors.
  Journal of the National Comprehensive Cancer Network : JNCCN 2013 Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott…
• Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.
  Breast cancer research and treatment 2013 Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA
• Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
  Current medical research and opinion 2013 Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki…
• Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, …
• Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
  European journal of cancer (Oxford, England : 1990) 2013 Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, …
• Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J
• A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
  Breast cancer research and treatment 2013 Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X
• First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
  The oncologist 2013 Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B, Quah C, Yardley D, Rugo HS
• Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
  Cancer 2013 Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, …
• Developing safety criteria for introducing new agents into neoadjuvant trials.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P…
• Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, …
• Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
  Journal of the National Cancer Institute 2013 Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, …
• Emerging treatments in chemotherapy-induced nausea and vomiting.
  Clinical advances in hematology & oncology : H&O 2013 Grunberg SM, Slusher B, Rugo HS
• New developments in metastatic breast cancer: general discussion.
  Clinical advances in hematology & oncology : H&O 2013 Vahdat LT, Rugo HS, Perez EA
• New developments in metastatic breast cancer: integrating recent data into clinical practice.
  Clinical advances in hematology & oncology : H&O 2013 Perez EA, Rugo HS, Vahdat LT
• New developments in metastatic breast cancer: introduction.
  Clinical advances in hematology & oncology : H&O 2013 Rugo HS
• Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions.
  Journal of the National Cancer Institute 2012 Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC
• Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B,…
• Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.
  Breast cancer research and treatment 2012 Chien AJ, Rugo HS
• Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients.
  Cancer research 2012 Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW
• Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer.
  Future oncology (London, England) 2012 Keck S, Glencer AC, Rugo HS
• Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
  Breast cancer research : BCR 2012 Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU
• Progress against solid tumors in danger: the metastatic breast cancer example.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN
• Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.
  Breast cancer research and treatment 2012 Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA
• A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.
  Cancer chemotherapy and pharmacology 2012 Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M
• The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.
  Breast cancer research and treatment 2012 Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M
• Patient perceptions of reproductive health counseling at the time of cancer diagnosis: a qualitative study of female California cancer survivors.
  Journal of cancer survivorship : research and practice 2012 Niemasik EE, Letourneau J, Dohan D, Katz A, Melisko M, Rugo H, Rosen M
• Reversing hormone resistance: have we found the golden key?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Rugo HS, Keck S
• The role of targeted therapy and biomarkers in breast cancer treatment.
  Clinical & experimental metastasis 2012 Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS
• Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J
• TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou…
• A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS
• Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT,…
• The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
  Cancer discovery 2012 Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, …
• Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery.
  The journal of pain 2012 McCann B, Miaskowski C, Koetters T, Baggott C, West C, Levine JD, Elboim C, Abrams G, Hamolsky D, Dunn L, Rugo H, Dodd M, Paul SM, Neuhaus J, Cooper B, Schmidt B, Langford D, Cataldo J, Aouizerat BE
• Antiemesis.
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, …
• 1st International consensus guidelines for advanced breast cancer (ABC 1).
  Breast (Edinburgh, Scotland) 2012 Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K,…
• Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial.
  Breast cancer research and treatment 2012 Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA
• Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Rugo HS
• Senior adult oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, …
• An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.
  Cancer 2012 Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN
• Neoadjuvant therapy for HER2-positive early-stage breast cancer: the future is almost here.
  Oncology (Williston Park, N.Y.) 2012 Rugo HS
• Clinical and biomarker predictors of side effects from tamoxifen.
  Breast cancer research and treatment 2011 Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E
• Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
  Breast cancer research and treatment 2011 Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, …
• A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
  Breast cancer research and treatment 2011 Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN
• Immune microenvironments in solid tumors: new targets for therapy.
  Genes & development 2011 Shiao SL, Ganesan AP, Rugo HS, Coussens LM
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
  The New England journal of medicine 2011 Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, …
• Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
  Clinical advances in hematology & oncology : H&O 2011 Rugo HS, O'Shaughnessy JA, Perez EA
• Current treatment options for metastatic breast cancer: what now?
  Clinical advances in hematology & oncology : H&O 2011 Rugo HS, O'Shaughnessy JA, Perez EA
• RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS
• Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment.
  Genome medicine 2011 Lorizio W, Rugo H, Beattie MS, Tchu S, Melese T, Melisko M, Wu AH, Lawrence HJ, Nikoloff M, Ziv E
• A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Mayer EL, Baurain JF, Sparano J, Strauss L, Campone M, Fumoleau P, Rugo H, Awada A, Sy O, Llombart-Cussac A
• Leukocyte composition of human breast cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2011 Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM
• New frontiers and treatment paradigms for metastatic breast cancer. A Review of an adjunct symposium of the 2011 American Society of Clinical Oncology Annual Meeting, June 4, 2011 Chicago, Illinois.
  Clinical advances in hematology & oncology : H&O 2011 Perez EA, Mooberry S, Twelves C, Rugo HS
• Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer.
  JAMA 2011 Rugo HS, Rosen MP
• Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA
• Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
  Cancer discovery 2011 DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM
• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
  British journal of cancer 2011 Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE
• Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D
• Systemic treatment of early breast cancer--a biological perspective.
  Journal of surgical oncology 2011 Greenberg S, Stopeck A, Rugo HS
• A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, …
• Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H
• Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
  Breast disease 2011 Li J, Rugo HS
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA
• Cost comparison of capecitabine in patients with breast cancer.
  American journal of clinical oncology 2010 Rugo HS, Kohles J, Schulman KL
• Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.
  Clinical breast cancer 2010 Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M
• Studying cancer-related fatigue: report of the NCCN scientific research committee.
  Journal of the National Comprehensive Cancer Network : JNCCN 2010 Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS
• Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
  Clinical breast cancer 2010 Greenberg S, Rugo HS
• Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.
  Clinical breast cancer 2010 Rugo H, Brammer M, Zhang F, Lalla D
• NCCN Clinical Practice Guidelines Cancer-related fatigue.
  Journal of the National Comprehensive Cancer Network : JNCCN 2010 Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, …
• Amelioration of sexual adverse effects in the early breast cancer patient.
  Journal of cancer survivorship : research and practice 2010 Melisko ME, Goldman M, Rugo HS
• Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
  Cancer treatment reviews 2010 Ortmann O, Pagani O, Jones A, Maass N, Noss D, Rugo H, van de Velde C, Aapro M, Coleman R
• The cardiac safety of trastuzumab in the treatment of breast cancer.
  Expert opinion on drug safety 2010 Chien AJ, Rugo HS
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J
• Triple-negative breast cancer: role of antiangiogenic agents.
  Cancer journal (Sudbury, Mass.) 2010 Greenberg S, Rugo HS
• Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE
• Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT
• Implementing decision and communication aids to facilitate patient-centered care in breast cancer: a case study.
  Patient education and counseling 2009 Belkora JK, Loth MK, Volz S, Rugo HS
• Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, Park JW, Geneus S, Paulson M, Grothusen J, Seidman AD, Fornier M, Lake D, Dang C, Robson M, Theodoulou M, Flombaum CD, Norton L, Hudis CA,…
• Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment.
  Journal of the American College of Surgeons 2009 Silverstein MJ, Recht A, Lagios MD, Bleiweiss IJ, Blumencranz PW, Gizienski T, Harms SE, Harness J, Jackman RJ, Klimberg VS, Kuske R, Levine GM, Linver MN, Rafferty EA, Rugo H, Schilling K, Tripathy D…
• Antiemesis. Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2009 Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, …
• Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.
  BMC cancer 2009 Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, …
• A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
  Cancer chemotherapy and pharmacology 2009 Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, Rugo HS
• Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
  Cancer treatment and research 2009 Jo Chien A, Rugo HS
• A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton…
• New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
  Nature clinical practice. Oncology 2008 Melisko ME, Glantz M, Rugo HS
• Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates.
  The Lancet. Oncology 2008 Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L
• The impact of sharing results of a randomized breast cancer clinical trial with study participants.
  Breast cancer research and treatment 2008 Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP
• Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival.
  Journal of neuro-oncology 2008 Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS
• Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD
• Novel taxane formulations in the treatment of breast cancer: a thought leader discussion and consensus roundtable.
  Clinical breast cancer 2008 Gralow J, Rugo H, Gradishar W, O'Shaughnessy JA, Jahanzeb M, Perez E, Tripathy D
• The importance of distant metastases in hormone-sensitive breast cancer.
  Breast (Edinburgh, Scotland) 2008 Rugo HS
• The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
  Annals of oncology : official journal of the European Society for Medical Oncology 2007 Rugo HS
• Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy.
  Archives of physical medicine and rehabilitation 2007 Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K
• Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial.
  Oncology nursing forum 2007 Dibble SL, Luce J, Cooper BA, Israel J, Cohen M, Nussey B, Rugo H
• Strategies for the prevention of treatment-related bone loss in women receiving adjuvant hormonal therapy.
  Clinical breast cancer 2007 Rugo HS
• Bevacizumab for advanced breast cancer.
  Hematology/oncology clinics of North America 2007 Traina TA, Rugo HS, Dickler M
• Hormonal therapy for advanced breast cancer.
  Hematology/oncology clinics of North America 2007 Rugo HS
• The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
  Current treatment options in oncology 2007 Lin A, Rugo HS
• Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer.
  Breast cancer research and treatment 2006 Rugo H, Shtivelman E, Perez A, Vogel C, Franco S, Tan Chiu E, Melisko M, Tagliaferri M, Cohen I, Shoemaker M, Tran Z, Tripathy D
• The role of angiogenesis inhibition in the treatment of breast cancer.
  Clinical advances in hematology & oncology : H&O 2006 Sledge GW, Rugo HS, Burstein HJ
• Targeting growth factors and angiogenesis; using small molecules in malignancy.
  Cancer metastasis reviews 2006 Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H
• Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006 Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C
• Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical.
  IDrugs : the investigational drugs journal 2005 Man M, Rugo H
• Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS
• Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G
• MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
  AJR. American journal of roentgenology 2005 Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM
• High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer.
  American journal of clinical oncology 2005 Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ
• Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers.
  Clinical breast cancer 2005 Melisko ME, Hassin F, Metzroth L, Moore DH, Brown B, Patel K, Rugo HS, Tripathy D
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS
• Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.
  Journal of the American College of Surgeons 2004 Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES
• Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
  Cancer chemotherapy and pharmacology 2004 Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA
• Bevacizumab in the treatment of breast cancer: rationale and current data.
  The oncologist 2004 Rugo HS
• The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research.
  Seminars in oncology 2003 Rugo HS, Ahles T
• Management of breast cancer diagnosed during pregnancy.
  Current treatment options in oncology 2003 Rugo HS
• Ocular manifestations of leukemia: leukemic infiltration versus infectious process.
  Ophthalmology 2001 Gordon KB, Rugo HS, Duncan JL, Irvine AR, Howes EL, O'Brien JM, Carter SR
• Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, …
• MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
  Annals of surgical oncology 2001 Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N
• NCCN Practice Guidelines for Cancer-Related Fatigue.
  Oncology (Williston Park, N.Y.) 2000 Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C…
• High-dose chemotherapy (CTM) for breast cancer.
  Bone marrow transplantation 2000 Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, Linker CA
• Autologous stem cell transplantation for acute myeloid leukemia in first remission.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2000 Linker CA, Ries CA, Damon LE, Sayre P, Navarro W, Rugo HS, Rubin A, Case D, Crilley P, Topolsky D, Brodsky I, Zamkoff K, Wolfe JL
• Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients.
  Bone marrow transplantation 2000 Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schiller GJ, White M, Jacobs C, DiPersio J, Anderson…
• Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
  Blood 1999 Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, …
• Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
  Bone marrow transplantation 1998 Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL
• A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia.
  Leukemia 1997 Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC, Beer M, Ahmed T
• High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997 Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA
• The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation.
  Endoscopy 1996 Terdiman JP, Linker CA, Ries CA, Damon LE, Rugo HS, Ostroff JW
• Bone marrow transplantation retinopathy in the absence of radiation therapy.
  American journal of ophthalmology 1996 Cunningham ET, Irvine AR, Rugo HS
• Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia.
  Bone marrow transplantation 1996 Damon LE, Rugo HS, Ries CA, Linker CA
• Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
  Leukemia 1994 Damon LE, Rugo HS, Ries CA, Linker CA
• High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma.
  Progress in clinical and biological research 1994 Rugo HS, Damon LE, Ries CA, Wolf JL, Linker CA
• Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
  Seminars in oncology 1993 Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL
• Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.
  Blood 1993 Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL
• Local cytokine production in a murine model of Escherichia coli pyelonephritis.
  The Journal of clinical investigation 1992 Rugo HS, O'Hanley P, Bishop AG, Pearce MK, Abrams JS, Howard M, O'Garra A
• Frequency and organization of papA homologous DNA sequences among uropathogenic digalactoside-binding Escherichia coli strains.
  Infection and immunity 1991 Denich K, Craiu A, Rugo H, Muralidhar G, O'Hanley P
• Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10.
  International immunology 1990 O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, Rugo H, Barbis D, Stall A, Cupp J, Moore K
• Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital.
  The American journal of medicine 1989 O'Hanley P, Easaw J, Rugo H, Easaw S